Great news for Alzheimer's patients, another drug is also ready for treatment
Scientists have developed two drugs for the first time to treat Alzheimer's disease, which causes mental degeneration after decades, which will help in reducing the spread of this disease.
According to media reports, in July 2023, the Food and Drug Administration (FDA) announced the approval of the first drug, the US and Japan had previously announced approval for the use of this drug.
The drug is called lecanemab and is being marketed as Leqembi and is an 'intravenous' (IV) injection, meaning that the injection will be given to the patient specially.
While the name of the other drug is donanemab, both of these injections can be administered to patients who will have early symptoms of Alzheimer's or dementia, but until now it has been approved by the Food and Drug Administration. Not approved.
Both drugs will be considered for approval by UK medical authorities next year, marking a significant advance in global efforts to tackle Alzheimer's disease.
The first drug called lecanimab is manufactured by the Japanese pharmaceutical company Eisa, while the second drug called donanimab is manufactured by the American Eli Lilly company.
This is a major breakthrough after years of research by scientists, and after decades of research, these drugs will bring hope to the lives of Alzheimer's patients.
David Thomas, head of policy at Alzheimer's Research UK, said: 'These new drugs slow the progression of Alzheimer's by six months to a year and are only useful for people with early symptoms of the disease, so we Can't call it 'miracle medicines'.
Both drugs are under consideration for approval in the UK next year, with the Medicines and Healthcare Products Regulatory Agency (MHRA) first deciding whether the drugs are safe and effective, then the National Institute for Health and Care Excellence. (NICE) will review the cost of these drugs.
Both drugs are expensive, according to the report, it is said that their price will start from 25 thousand dollars.
It is also worth mentioning here that these are the first drugs of their kind that have been specially developed for patients of 'Alzheimer'. are being treated.
It is too early to say how long the drug will be available in other countries after the US, UK, and Japan, but the drug will likely be available in other countries after three years.
It should be noted that Alzheimer's is a disease that was said to have no complete cure yet and it slowly pushes the patient towards death.
The disease affects the brain, causing memory loss and a specific type of protein that triggers it.